Back to News
Top StoriesMarketWatch3h ago
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
Read Full Article on MarketWatchMore Top Stories News
From $6 eggs to $50,000 cars, these charts show how inflation has defined the past 5 years
MarketWatch·1h ago
Why the alternative to the ‘clear and present’ danger from bond yields is this AI-fueled market that has quietly outperformed
MarketWatch·2h ago
‘We were wrong.’ Why Morgan Stanley changed its tune on the U.S. dollar — and what it expects now.
MarketWatch·2h ago
The low-key California property portfolio of ‘Wednesday’ star Jenna Ortega
MarketWatch·4h ago
Akamai’s stock is surging. A $12 billion Anthropic deal reveals its powerful edge over cloud providers.
MarketWatch·4h ago
Content sourced from MarketWatch. Not financial advice.